Is BALPHARMA undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6
Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of BALPHARMA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: BALPHARMA (₹134.5) is trading below our estimate of fair value (₹1309.57)
Significantly Below Fair Value: BALPHARMA is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BALPHARMA?
Key metric: As BALPHARMA is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
The above table shows the Price to Earnings ratio for BALPHARMA. This is calculated by dividing BALPHARMA's market cap by their current
earnings.
What is BALPHARMA's PE Ratio?
PE Ratio
28.2x
Earnings
₹76.63m
Market Cap
₹2.16b
BALPHARMA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue
1.1x
Enterprise Value/EBITDA
11.6x
PEG Ratio
n/a
Price to Earnings Ratio vs Peers
How does BALPHARMA's PE Ratio compare to its peers?
Price-To-Earnings vs Industry: BALPHARMA is good value based on its Price-To-Earnings Ratio (28.2x) compared to the Indian Pharmaceuticals industry average (32.2x).
Price to Earnings Ratio vs Fair Ratio
What is BALPHARMA's PE Ratio
compared to its
Fair PE Ratio?
This is the expected PE Ratio taking into
account the company's forecast earnings growth, profit margins
and other risk factors.
BALPHARMA PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio
28.2x
Fair PE Ratio
n/a
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate BALPHARMA's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.